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quantities by many primary and metastatic cancers (2) (3) (4) (5) (6) (7) (8) . As a result, "folate targeting" has been successfully applied toward the delivery of a wide variety of therapeutic-and imaging-based agents to tumors that express the FR protein (9) (10) (11) (12) . Compared to their nontargeted counterparts, FA-bearing drugs and delivery systems have repeatedly shown greater cancer cell specificity and selectivity in numerous preclinical studies (13) (14) (15) (16) (17) (18) (19) (20) . Hence, this targeting strategy leads to improvements in the safety and efficacy of anticancer agents, resulting in an increased therapeutic advantage.
We have recently described the biologic activity of vintafolide (EC145), a folate conjugate of the microtubuledestabilizing agent, desacetylvinblastine (DAVLBH; a derivative of the natural product, vinblastine) (18, 19) . DAVLBH was chosen as the drug moiety for vintafolide because it contains a modifiable hydrazide functional group to which one can attach a hydrophilic folate-peptide compound (eg, FA-Asp-Arg-Asp-Asp-Cys) via a disulfide linker. Vintafolide was determined to have high affinity for the FR, and it is extremely potent in vitro against FR-expressing cells with IC 50 s in the low nanomolar range (19) . When evaluated against FR-expressing tumor xenograft models, vintafolide produces impressive antitumor activity, with complete responses or cures in 100% of the tumors under conditions that produce little to no toxicity.
Clinically, single-agent vintafolide was shown to be well tolerated by patients, with constipation and mild peripheral neuropathy being the dose-limiting toxicities, especially in patients with lower vintafolide clearance (21) .
Importantly, vintafolide did not cause appreciable hematopoietic toxicity, which is very common among standard-ofcare chemotherapeutic agents.
Current practice in clinical oncology is to utilize multidrug combinations instead of single-agent chemotherapy.
Such regimens are designed to take advantage of non-overlapping tissue toxicity and antitumor activity against differentially resistant cancer cell clones. In an attempt to prioritize and guide future vintafolide clinical studies, we assessed the therapeutic effects of various vintafolide-based combination regimens relative to single-agent therapies against FR-expressing cells and tumor models. Pegylated liposomal doxorubicin (PLD; which causes stomatitis and Author Manuscript Published OnlineFirst on January 15, 2014; DOI: 10.1158/1078-0432.CCR- palmar-plantar syndrome), paclitaxel, docetaxel, topotecan, and irinotecan (neutropenia), cisplatin (neurotoxicity), and carboplatin (myelosuppression) were all chosen for study due to their non-overlapping dose-limiting toxicities compared to vintafolide. Herein we present the results of binary combinations of vintafolide with each of these 7 clinically relevant anticancer agents.
MATERIALS AND METHODS

Materials
Vintafolide (Endocyte Inc.) clinical vial solutions were used in all the experiments. Doxorubicin, carboplatin, and cisplatin were purchased from Sigma, St. Louis, MO; PLD (DOXIL ® ) and docetaxel was obtained from the Purdue Pharmacy, West Lafayette, IN; paclitaxel, topotecan, and irinotecan were purchased from A.K. Scientific, Mountain View, CA. All other common reagents were purchased from Sigma or other major suppliers.
Estimation of surface FR's on various cell lines
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Author Manuscript Published OnlineFirst on January 15, 2014; DOI: 10.1158/1078-0432.CCR- To quantify the number of cell surface FR's, 1 x 10 6 cells were harvested and transferred in 1 ml of FD-RPMI + 10 % FCS to a 5 ml polypropylene tube in triplicates. as the drug concentration that inhibited cell growth by 60% (IC 60 ) determined from concentration-effect relationships using GraphPad prism.
Analysis of combined drug effects
Drug synergy was determined by the isobologram and combination-index methods derived from the medianeffect principle of Chou and Talalay (22) . Data obtained from the growth-inhibitory experiments were used to perform these analyses. The isobologram is a graphical representation of the drug interaction and is formed by selecting a desired cell kill fraction (60% in this case) and plotting the individual drug doses required to generate that fraction on the respective x-and y-axes. A straight line is then drawn to connect the points. Multiple combinations of corresponding drug concentrations that achieved the 60% growth inhibition effect are plotted in the isobologram.
Combination data points that fall on the line represent an additive drug-drug interaction, whereas data points that fall below or above the line represent synergism or antagonism, respectively. The combination-index (CI) method is a , where L = measurement of longest axis in mm and W = measurement of axis perpendicular to L in mm. As a general measure of gross toxicity, changes in body weights were determined on the same schedule as tumor volume measurements.
Maximum percentage weight loss on any given day due to treatment was determined for each mouse and the average for the group is reported as Average of Maximum % Weight Loss (AMWL %). Survival of animals was monitored daily. Animals that were moribund (or unable to reach food or water) were euthanized by CO 2 asphyxiation. All animal housing, care, and procedures were followed according to Purdue Animal Care and Use
Committee (PACUC)-approved animal care and use protocols.
Tumor response criteria
Individual tumor response endpoints were reported in terms of tumor volume change. A partial response (PR) was defined as volume regression >50% but with measurable tumor (>2 mm The vintafolide/doxorubicin combination effect was also tested against FR-positive IGROV and L1210 cells, and no more than an additive effect was observed in both cell lines. This is presumably because both of these cell lines are less sensitive to the vinca alkaloid base drug causing vintafolide's IC50 to be greater than 1 μM. At such higher concentrations of vintafolide, we have observed that the level of competition with folic acid is reduced, indicating Finally, to confirm the importance of vintafolide's FR targeting ability to synergize with doxorubicin, the vintafolide/doxorubicin combination was also tested against the FR-negative A549 cell line. Here, vintafolide alone was not found to be active up to 1 μM, while doxorubicin by itself was active against these cells with an IC 50 of 27 nM.
When combined with even high concentrations of vintafolide (500 to 1000 nM), the dose response curves looked identical to doxorubicin alone with no reduction in the IC 50 values of the combination groups ( Fig. 2A) , thus indicating that the aforementioned combination drug effects are dependent on FR expression. 
FR-targeted vintafolide displays synergistic in vivo antitumor effect when combined with pegylated liposomal doxorubicin
The observed in vitro synergistic activity between vintafolide and doxorubicin prompted a similar investigation using tumor-bearing mice. Owing to the unfavorable toxicity profile of doxorubicin (23), PLD was used in combination with vintafolide for in vivo studies involving FR-positive KB, M109, IGROV, and L1210 tumor models. Since each of these tumor types will respond to single-agent vintafolide therapy, suboptimal non-curative dosing regimens of vintafolide were used to better determine the benefits of combining with PLD. Thus, vintafolide was administered using vintafolide Regimen-A [1 μmol/kg, 3 times a week (TIW) for 2 weeks] or vintafolide Regimen-B (2 μmol/kg, TIW for 2 weeks). PLD was also administered at 1 of 2 regimens [PLD-A, 4 mg/kg twice a week (BIW) for 2 weeks; or PLD-B, 4 mg/kg once a week for 3 weeks] that represent 50 to 75% of the MTD range for the murine species used in these studies. Importantly, among the combination groups, if both agents had to be administered on the same day, PLD was always dosed 4 h following vintafolide administration.
Athymic nude mice with established subcutaneous KB xenografts were treated with vintafolide Regimen-A, PLD-A, or the respective drug combination. As shown in Table 1 and Fig. 3A , single-agent vintafolide produced minor antitumor activity with 20% PR and LCK of 1.2. Single-agent PLD was more active against this model, with 20% PRs, 40% CRs, and LCK value of 3.5; plus, 20% of the mice in this cohort were cured. However, the vintafolide/PLD combination generated greater antitumor activity, where 20% of the animals displayed CRs, and more impressively, 80% of the animals were cured. The uncured tumor did have an LCK value of 4.8, indicating strong antitumor effect.
Some weight loss occurred in the combination cohort (AMWL% 8.2), which was mostly attributed to PLD since the single-agent PLD cohort had an AMWL of 6.6%. In contrast, the single-agent vintafolide cohort had an AMWL of only 0.7% (Table 1) .
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When tested against the M109 tumor-Balb/c mouse model, vintafolide Regimen-B produced 60% cures (LCK of 0.7), whereas PLD-B generated 60% cures and 20% CRs (LCK of 2.2) (Table 1, Fig. 3B ). However, the combination of these two drugs resulted in an impressive 100% cure rate. Fig. 3D ). In all 3 models the AMWL% for the combination groups was in the 3.5 to 4% range (Table 1) , whereas the single-agent PLD cohorts were in the 1.6 to 3.8% range, and the single-agent vintafolide cohorts were in the 1 to 2.4% range. Vintafolide/PLD combinations were also tested in nu/nu mice implanted with RAW tumors. Unfortunately the RAW tumors were found to be far less sensitive than their cellular form, with vintafolide at 2 μmol/kg, TIW x 2, DOXIL at 4 mg/kg, BIW x 2 and their combination producing 0 PR's in all the three groups. We have seen similar results with the J6456 tumors, i.e. unlike their cellular counterparts which are far more sensitive to vintafolide and doxorubicin, thus making it impossible to determine the advantage of a combination treatment in vivo.
Weight losses in each group of every study were observed during the dosing periods, or within a week after the last dose, but the mice recovered to their pre-treatment weights soon thereafter. The weight loss seen on days 28-30 in the M109 control group was due to the tumors reaching a volume greater than 1000 mm 
Since drug "targeting" to the FR was shown to be an essential component of the in vitro synergistic activity observed between the vinca-alkaloid-containing agent vintafolide and doxorubicin (Fig. 1) , the validity of this drug delivery approach was tested in vivo by determining the antitumor activity of nontargeted vinca alkaloids in combination with PLD. Here, athymic nude mice with established subcutaneous xenograft KB tumors were treated with DAVLBH, vindesine, PLD, or their respective combinations. DAVLBH and vindesine were administered at dose levels 20% below those that would cause 5% weight loss following a schedule similar to that of vintafolide (ie, TIW for 
Vintafolide combines synergistically with anticancer agents of varying mechanisms of action
The potential of vintafolide to combine with other clinically relevant anticancer agents was evaluated using drugs with differing mechanisms of action. For this study we selected agents commonly used in treating advanced ovarian cancer patients, such as DNA crosslinking agents (cisplatin and carboplatin), microtubule inhibitors (paclitaxel and docetaxel), and topoisomerase inhibitors (topotecan and irinotecan). In vitro, vintafolide's combination results 1 1 μmol/kg of DAVLBH caused weight loss of up to 14%; see Ref 18 Research. varied from strong synergistic effect with topotecan (CI=0.49), to slightly less than additive effects with paclitaxel (CI=1.15).
All of these approved drugs were tested in combination using vintafolide Regimen-A (1 μmol/kg, TIW for 2 consecutive weeks) against the KB tumor-nu/nu mouse model. Single-agent vintafolide produced some antitumor activity ranging from 0% PRs to 20% cures, and LCK ranging from 0.6 to 1.7 (Table 2, Fig. 4) . When tested at 3 mg/kg BIW for 2 weeks, the DNA crosslinker cisplatin yielded a modest antitumor effect of 40% PRs and LCK of 1.8, whereas combining it with vintafolide generated a striking 100% cure rate ( Table 2 , Fig. 4A) . Similarly, single-agent carboplatin dosed at 50 mg/kg TIW produced 60% PRs and LCK of 2.0; its combination with vintafolide resulted in an 80% cure rate, 20% CR, and LCK of 4.4 (Table 2, Fig. 4B ). Importantly, the weight loss seen with both of these crosslinking agents (10.5% vs 5.9% for cisplatin and carboplatin, respectively) was not exacerbated by the addition of vintafolide (cisplatin: 11.9% vs 5.3% for vintafolide/cisplatin and vintafolide/carboplatin, respectively).
As single agents, the microtubule inhibitors paclitaxel (40 mg/kg, SIW for 3 weeks) and docetaxel (10 mg/kg, TIW for 1 week) produced nominal antitumor activity, with 40% and 0% PRs, respectively. When combined with vintafolide, paclitaxel produced stronger antitumor effect, with 40% cures, 60% CRs, and LCK of 2.5 ( Table 2 , Fig. 4C ).
Both the single-agent and the combination cohorts were not accompanied by significant weight loss (AMWL of 2.3% and 2.8%, respectively). Interestingly, the vintafolide/docetaxel combination produced superior efficacy, where 100% of the treated mice were cured (Table 2, Fig. 4D ). In addition, weight loss in the combination group appeared to be much less severe (10.5%) compared to the single-agent docetaxel group (16.3%), a finding that was reproducibly observed in subsequent vintafolide/docetaxel studies (data not shown).
Significantly greater antitumor effect was also observed when vintafolide was combined with topoisomerase inhibitors. Thus, as single agents, topotecan (5 mg/kg, TIW for 2 weeks) and irinotecan (20 mg/kg, BIW for 2 weeks) produced minimal antitumor activity (0% PRs) against KB tumors. In contrast, the vintafolide/topotecan combination produced 40% CRs and 60% PRs, with LCK of 2.4; the vintafolide/irinotecan combination produced 60% cures and 40% Fig. 4E and F) . Once again, compared to the single-agent groups, where AMWL was 11.8% vs 1.2% for topotecan and irinotecan, respectively, the health of the mice in the combination groups was not worsened by the addition of vintafolide (AMWL 6.7% vs 1.4% for topotecan and irinotecan, respectively). Together with the aforementioned combination data, these results show that vintafolide can combine with various anticancer drugs, of diverse mechanisms of action, to produce superior antitumor effect over the single agent under conditions that produce little to no added toxicity.
DISCUSSION
Since most standard chemotherapy regimens in the clinic utilize multidrug combinations, the goal of these studies was to determine if vintafolide, an FR-targeted vinca alkaloid conjugate, could favorably be combined with clinically approved agents, of various mechanisms of action, to improve therapeutic efficacy. The combination effect of vintafolide was first investigated with PLD, since this agent is a widely used second-line treatment of recurrent ovarian cancer, and vintafolide was recently found to be active against this indication in a single-agent, phase 2 clinical trial (24) . The mild toxicity profile of PLD renders it an ideal partner and comparator arm for evaluating combination regimens.
For cell-based studies, we chose to use doxorubicin (the active drug component in PLD) instead of PLD because the liposomal formulation has no cytotoxic activity in vitro. Under these conditions we found that vintafolide combined extremely well (additive to synergistic effects) with doxorubicin in each of 4 FR-positive cell lines tested.
When evaluated in vivo, a suboptimal dose of vintafolide was commonly used because chances of observing an enhanced therapeutic effect of any combination regimen would have been limited due to potential curative activity of "optimal" single-agent vintafolide therapy (18, 19, 25) . Our results showed that when combined with PLD, vintafolide produced superior antitumor activity compared to the individual drugs administered as single agents. In After initial tumor debulking surgery, a majority of ovarian cancer patients receive a first-line combination regimen that comprises a platinum drug (cisplatin or carboplatin) (26) and a taxane (paclitaxel or docetaxel) (27, 28) .
To address the potential of vintafolide to replace one of these drugs, we evaluated the antitumor effect of 2 Greater than 90% of 111 In-DTPA-folate tumor uptake was retained in the tumor at a 24 h time point, when compared to a 30 minute time point (26) 3 Folate conjugate internalization has a rate of 1-3 x 10 5 molecules/h, with 10-25% internalized in 6 h across various cell lines (27) Research. 
combinations where either the taxane or the platinum agent was substituted with vintafolide. When a taxane was replaced with vintafolide, the combinations with cisplatin and carboplatin produced remarkable antitumor activity in our models, with up to 100% cure rates. When a platinum agent was replaced with vintafolide, the combinations with paclitaxel and docetaxel also produced notable antitumor activity, also with up to 100% cure rates. In all 4 combinations, the antitumor activity of the combinations was far superior to that observed with any of the individual drugs tested alone. In addition, combining vintafolide with any of these agents was found not to increase the inherent toxicity/weight loss above that produced by the untargeted single agents.
Topoisomerase I inhibitors, such as topotecan and irinotecan, have also been shown to be effective treatment options for advanced or relapsed ovarian cancer patients (29, 30) . These agents are generally tolerated, with associated hematologic toxicities being manageable, reversible, and noncumulative. When combined with vintafolide, both topotecan and irinotecan produced superior activity over single-agent therapy. In fact, CRs and cures were only observed in the combination cohorts. Surprisingly, the health of the treated mice in the combination cohorts was slightly better as compared to the single-agent cohorts. Although the reason for this effect is not understood at this time, it is reproducible and warrants further study into this apparent drug-drug interaction.
Combination therapy may be especially useful when deployed in a cell-targeted therapy scenario because i) tumor cells can express varying levels of the cell surface receptor, and ii) some cancer cells may not express the receptor at all. This can be challenging for targeted agents such as vintafolide that are constructed using cytotoxic moieties that must bind to and be internalized within receptor-expressing cells to exert their effect. FR "heterogeneity" within tumor lesions is a concern, but it may be overcome by the use of vintafolide in a noncompetitive combination setting using drugs that have different mechanisms of action. Other possible mechanisms of reduced activity, such as emergence of resistant cell populations, or FR-negative clones that cannot be effectively treated with single-agent therapy, may also be obviated by using a rational combination approach. 
The vintafolide/PLD combination therapy provided an enhanced therapeutic benefit and appeared to be synergistic in various FR-positive tumor models in our laboratory. In the clinic, vinca alkaloids, such as vinorelbine (31) , have shown good activity against cisplatin-resistant ovarian cancer, with a favorable toxicity profile. PLD is also well tolerated with non-overlapping toxicity to vinca alkaloids, and it has well-documented clinical activity against ovarian cancer. Based on the preclinical results presented above, together with positive phase 2 single-agent results of vintafolide for treatment of advanced ovarian cancer (24) , our team initiated a randomized phase 2 trial (PRECEDENT) comparing PLD versus a vintafolide/PLD combination in women with platinum-resistant ovarian cancer.
The trial was completed in 2012, and results confirmed that the vintafolide/PLD combination provided, for the first time, a statistically significant higher progression-free survival rate in FR-positive patients when compared to PLD alone(1) Based on these promising results, the vintafolide/PLD combination is currently being evaluated in the PROCEED trial (sponsored by Merck and Endocyte), which is a global, randomized, phase 3 study in women with platinum-resistant ovarian cancer.
CONCLUSIONS
The high percentage of complete responses and 90-day survivors (ie, cures) in 7 preclinical, binary treatment regimens highlighted the potential of vintafolide to yield enhanced clinical therapeutic effect with these agents in a combination setting. Our preclinical findings thus provide a rationale for the design of clinical studies combining vintafolide with approved chemotherapeutic agents such as PLD, platinum agents, topoisomerase inhibitors, and taxanes, with the goal of achieving improved efficacy, acceptable safety, and reduced long-term complications to patients. 
